Drugs / M3T01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06719362 | Jun 2025 → Feb 2028 expected | cancer | Providence Health & Services | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M3T01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06719362 ↗ |
| Modality | Monoclonal antibody | “fully human IgG4/kappa monoclonal antibody” NCT06719362 ↗ |
| Route | Intravenous | “Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.” NCT06719362 ↗ |
| Target | FASLG | “targeting FasL” NCT06719362 ↗ |